BR112022017102A2 - Métodos para tratar esclerose múltipla progressiva primária (ppms), retardar a progressão de ppms, retardar o início de pelo menos um evento de progressão em um indivíduo com ppms, reduzir o risco de um indivíduo com ppms ter pelo menos um evento de progressão e reduzir a deficiência em um indivíduo com ppms e compostos - Google Patents
Métodos para tratar esclerose múltipla progressiva primária (ppms), retardar a progressão de ppms, retardar o início de pelo menos um evento de progressão em um indivíduo com ppms, reduzir o risco de um indivíduo com ppms ter pelo menos um evento de progressão e reduzir a deficiência em um indivíduo com ppms e compostosInfo
- Publication number
- BR112022017102A2 BR112022017102A2 BR112022017102A BR112022017102A BR112022017102A2 BR 112022017102 A2 BR112022017102 A2 BR 112022017102A2 BR 112022017102 A BR112022017102 A BR 112022017102A BR 112022017102 A BR112022017102 A BR 112022017102A BR 112022017102 A2 BR112022017102 A2 BR 112022017102A2
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- progression
- ppms
- delay
- reduce
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982872P | 2020-02-28 | 2020-02-28 | |
| US202063051756P | 2020-07-14 | 2020-07-14 | |
| PCT/US2021/019502 WO2021173740A1 (en) | 2020-02-28 | 2021-02-25 | Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022017102A2 true BR112022017102A2 (pt) | 2022-11-16 |
Family
ID=74885089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022017102A BR112022017102A2 (pt) | 2020-02-28 | 2021-02-25 | Métodos para tratar esclerose múltipla progressiva primária (ppms), retardar a progressão de ppms, retardar o início de pelo menos um evento de progressão em um indivíduo com ppms, reduzir o risco de um indivíduo com ppms ter pelo menos um evento de progressão e reduzir a deficiência em um indivíduo com ppms e compostos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230091561A1 (https=) |
| EP (1) | EP4110339A1 (https=) |
| JP (1) | JP2023515528A (https=) |
| KR (1) | KR20220148826A (https=) |
| CN (1) | CN115175682A (https=) |
| AU (1) | AU2021227674A1 (https=) |
| BR (1) | BR112022017102A2 (https=) |
| CA (1) | CA3170685A1 (https=) |
| CL (1) | CL2022002317A1 (https=) |
| IL (1) | IL295476A (https=) |
| MX (1) | MX2022010513A (https=) |
| TW (1) | TWI899163B (https=) |
| WO (1) | WO2021173740A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021249129A1 (en) | 2020-04-03 | 2022-10-20 | F. Hoffmann-La Roche Ag | Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase |
| CN114028393B (zh) * | 2021-11-07 | 2023-07-18 | 天津医科大学 | 阿帕替尼在制备治疗多发性硬化症药物的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| EP4732904A2 (en) * | 2015-10-06 | 2026-04-29 | F. Hoffmann-La Roche AG | Method for treating multiple sclerosis |
| EP4049660B1 (en) | 2016-02-29 | 2025-02-19 | F. Hoffmann-La Roche AG | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
| CN110382052A (zh) * | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| MX2021000094A (es) * | 2018-07-20 | 2021-03-25 | Merck Patent Gmbh | Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple. |
| AU2021249129A1 (en) * | 2020-04-03 | 2022-10-20 | F. Hoffmann-La Roche Ag | Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase |
-
2021
- 2021-02-25 MX MX2022010513A patent/MX2022010513A/es unknown
- 2021-02-25 CN CN202180017387.XA patent/CN115175682A/zh active Pending
- 2021-02-25 TW TW110106714A patent/TWI899163B/zh active
- 2021-02-25 BR BR112022017102A patent/BR112022017102A2/pt unknown
- 2021-02-25 EP EP21712677.0A patent/EP4110339A1/en active Pending
- 2021-02-25 CA CA3170685A patent/CA3170685A1/en active Pending
- 2021-02-25 US US17/905,121 patent/US20230091561A1/en active Pending
- 2021-02-25 IL IL295476A patent/IL295476A/en unknown
- 2021-02-25 WO PCT/US2021/019502 patent/WO2021173740A1/en not_active Ceased
- 2021-02-25 JP JP2022550934A patent/JP2023515528A/ja not_active Withdrawn
- 2021-02-25 KR KR1020227030440A patent/KR20220148826A/ko active Pending
- 2021-02-25 AU AU2021227674A patent/AU2021227674A1/en active Pending
-
2022
- 2022-08-24 CL CL2022002317A patent/CL2022002317A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115175682A (zh) | 2022-10-11 |
| KR20220148826A (ko) | 2022-11-07 |
| US20230091561A1 (en) | 2023-03-23 |
| WO2021173740A1 (en) | 2021-09-02 |
| JP2023515528A (ja) | 2023-04-13 |
| CL2022002317A1 (es) | 2023-03-03 |
| EP4110339A1 (en) | 2023-01-04 |
| MX2022010513A (es) | 2022-09-21 |
| AU2021227674A1 (en) | 2022-07-21 |
| CA3170685A1 (en) | 2021-09-02 |
| TW202146022A (zh) | 2021-12-16 |
| TWI899163B (zh) | 2025-10-01 |
| IL295476A (en) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
| WO2020093006A8 (en) | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| BR112022004474A8 (pt) | Método de tratamento ou prevenção de um câncer em um sujeito, molécula de ligação ao antígeno para uso neste e uso desta | |
| BR112022011951A2 (pt) | Tratamento de esclerose lateral amiotrófica e distúrbios relacionados | |
| BR112022000231A2 (pt) | Novos métodos | |
| EA202190749A1 (ru) | Способы комбинированной терапии | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| MX2023002321A (es) | Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados. | |
| BR112022002609A2 (pt) | Métodos de tratamento de tumores estromais gastrointestinais | |
| BR112022026186A2 (pt) | Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras | |
| BR112022017102A2 (pt) | Métodos para tratar esclerose múltipla progressiva primária (ppms), retardar a progressão de ppms, retardar o início de pelo menos um evento de progressão em um indivíduo com ppms, reduzir o risco de um indivíduo com ppms ter pelo menos um evento de progressão e reduzir a deficiência em um indivíduo com ppms e compostos | |
| BR112023002089A2 (pt) | Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4 | |
| BR112022022578A2 (pt) | Novas composições e métodos de tratar doença covid-19 | |
| SA520420909B1 (ar) | تثبيط بروتين رابط لـ creb (cbp) | |
| EA202190776A1 (ru) | Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами | |
| EP4279127A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| WO2022240971A3 (en) | Kras g12d inhibitors and uses thereof | |
| BR112022025946A2 (pt) | Composto, composição farmacêutica e método de tratamento de uma doença | |
| MX2022010258A (es) | Composiciones y métodos para tratar la lesión renal. | |
| BR112022015800A2 (pt) | Tratamento de colangite biliar primária com elafibranor | |
| MX2022012310A (es) | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. | |
| MX2021012824A (es) | Métodos para tratar el prurito. | |
| MX2022012632A (es) | Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington. | |
| BR112022003686A2 (pt) | Tratamento de sintomas induzidos pelo ciclo menstrual |